Paul J Hagerman Selected Research

Fragile X Tremor Ataxia Syndrome

1/2021	Corrigendum: Human Cerebral Cortex Proteome of Fragile X-Associated Tremor/Ataxia Syndrome.
1/2020	Human Cerebral Cortex Proteome of Fragile X-Associated Tremor/Ataxia Syndrome.
1/2019	Composition of the Intranuclear Inclusions of Fragile X-associated Tremor/Ataxia Syndrome.
1/2019	Astroglial-targeted expression of the fragile X CGG repeat premutation in mice yields RAN translation, motor deficits and possible evidence for cell-to-cell propagation of FXTAS pathology.
1/2017	Calcium dysregulation and Cdk5-ATM pathway involved in a mouse model of fragile X-associated tremor/ataxia syndrome.
10/2016	A Majority of FXTAS Cases Present with Intranuclear Inclusions Within Purkinje Cells.
11/2014	Memantine effects on verbal memory in fragile X-associated tremor/ataxia syndrome (FXTAS): a double-blind brain potential study.
9/2014	Expression of an expanded CGG-repeat RNA in a single pair of primary sensory neurons impairs olfactory adaptation in Caenorhabditis elegans.
6/2014	CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size.
4/2014	Transcription-associated R-loop formation across the human FMR1 CGG-repeat region.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul J Hagerman Research Topics

Disease

44	Fragile X Tremor Ataxia Syndrome 01/2021 - 01/2004
21	Intellectual Disability (Idiocy) 01/2019 - 01/2003
18	Fragile X Syndrome (Martin Bell Syndrome) 01/2019 - 10/2003
12	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 07/2004
3	Tremor (Tremors) 03/2014 - 05/2003
2	Alzheimer Disease (Alzheimer's Disease) 11/2014 - 03/2014
2	Disease Progression 08/2011 - 06/2011
2	Autistic Disorder (Autism) 08/2011 - 11/2008
2	Parkinson Disease (Parkinson's Disease) 02/2009 - 07/2007
2	Ataxia (Dyssynergia) 10/2006 - 05/2003
2	Movement Disorders (Movement Disorder) 10/2006 - 01/2003
1	Neurodevelopmental Disorders 01/2022
1	Inflammation (Inflammations) 01/2020
1	Autism Spectrum Disorder 06/2014
1	Neurobehavioral Manifestations 03/2014
1	Protein Deficiency 01/2014
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2014
1	Hypersensitivity (Allergy) 05/2013
1	Friedreich Ataxia (Friedreich's Ataxia) 08/2011
1	Gait Ataxia 08/2011
1	Neuroblastoma 06/2011
1	Brain Diseases (Brain Disorder) 08/2010
1	Autoimmune Diseases (Autoimmune Disease) 08/2008
1	Myotonic Dystrophy (Dystrophia Myotonica) 04/2007
1	Central Nervous System Diseases (CNS Diseases) 01/2007
1	Cognitive Dysfunction 10/2006
1	Memory Disorders (Memory Loss) 10/2006
1	Parkinsonian Disorders (Parkinsonism) 10/2006
1	Laminopathies 12/2005
1	Mental Disorders (Mental Disorder) 11/2005
1	Learning Disabilities (Learning Disability) 01/2004

Drug/Important Bio-Agent (IBA)

29	Messenger RNA (mRNA)IBA 09/2014 - 01/2003
15	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2003
12	5' Untranslated Regions (5' UTR)IBA 01/2019 - 10/2003
12	RNA (Ribonucleic Acid)IBA 04/2014 - 07/2004
7	ElementsIBA 06/2014 - 12/2003
3	UbiquitinIBA 10/2016 - 05/2003
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 11/2014 - 05/2013
3	Fragile X Mental Retardation ProteinIBA 05/2013 - 01/2003
3	Lamin Type A (Lamin A)IBA 01/2010 - 12/2005
3	DNA (Deoxyribonucleic Acid)IBA 02/2009 - 07/2007
2	ProteomeIBA 01/2021 - 01/2020
2	Peptides (Polypeptides)IBA 01/2020 - 01/2019
2	Memantine (Namenda)FDA Link 11/2014 - 03/2014
2	MicroRNAs (MicroRNA)IBA 09/2014 - 03/2013
2	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2012 - 04/2010
2	Mitochondrial Proteins (Mitochondrial Protein)IBA 08/2011 - 08/2010
1	phosphoserine aminotransferase (phosphoserine transaminase)IBA 01/2020
1	TenascinIBA 01/2020
1	enhanced green fluorescent proteinIBA 01/2019
1	CalciumIBA 01/2017
1	Type II Bone Morphogenetic Protein Receptors (Bone Morphogenetic Protein Receptor Type II)IBA 01/2016
1	Glutamic Acid (Glutamate)FDA Link 11/2014
1	Biological ProductsIBA 09/2014
1	Adenosine Triphosphatases (ATPase)IBA 08/2011
1	FrataxinIBA 08/2011
1	Aconitate Hydratase (Aconitase)IBA 08/2011
1	oligomycin sensitivity-conferring protein (complex V)IBA 08/2011
1	IronIBA 08/2011
1	ZincIBA 08/2011
1	Untranslated Regions (Untranslated Region)IBA 08/2011
1	Doxycycline (Periostat)FDA LinkGeneric 06/2011
1	NAD (NADH)IBA 08/2010
1	Oxygen (Dioxygen)IBA 08/2010
1	Adenosine Triphosphate (ATP)IBA 08/2010
1	NeurotoxinsIBA 08/2010
1	Flavin-Adenine Dinucleotide (FAD)IBA 08/2010
1	Crystallins (Crystallin)IBA 08/2008
1	Biomarkers (Surrogate Marker)IBA 06/2008
1	NestinIBA 01/2005
1	CytosineIBA 01/2004
1	GuanineIBA 01/2004

Therapy/Procedure

2	Therapeutics 09/2012 - 10/2006
1	Activities of Daily Living (ADL) 10/2009